Tomoki Kosugi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomoki Kosugi has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Kenji Kadomatsu
Institute for Glyco-Core Research (iGCORE), Nagoya University, Nagoya, Japan
9 shared publicationsShoichi Maruyama
Department of Nephrology Nagoya University Graduate School of Medicine Nagoya Japan
8 shared publicationsKayaho Maeda
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
7 shared publicationsNoritoshi Kato
Department of Nephrology Nagoya University Graduate School of Medicine Nagoya Japan
6 shared publicationsYuka Sato
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
6 shared publications- Takuji Ishimoto
Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan
4 shared publications
Latest Publications
- Open Access
- 3 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (6) , 900-913
Ameliorative Effect of an Anti–MicroRNA-21 Oligonucleotide on Animal and Human Models of Cystic Kidney Disease
Key Points: Systemically administered anti–microRNA (miR)-21-serinol nucleic acid (SNA) accumulates in the kidneys and suppresses renal cyst growth. Anti–miR-21-SNA treatment alters mitochondrial metabolism, apoptotic signaling, and inhibits kidney tissue fibrosis. In human autosomal dominant polycystic kidney disease kidney cells, anti–miR-21-SNA treatment reduces cyst size and intracellular cAMP content and increases Ca2+ concentration. Background: Hereditary cystic kidney diseases are ciliopathies characterized by functional defects in the primary cilia of renal tubules. Abnormalities in the primary cilia enhance cell proliferation signals and cause cyst enlargement. The most common type is autosomal dominant polycystic kidney disease (ADPKD), but other diseases, such as nephronophthisis, have been discovered to be more common than previously considered. In ADPKD, several microRNAs are reportedly aberrantly expressed and involved in disease pathogenesis. Among these, we focused on microRNA (miR)-21, which is upregulated in response to cAMP signaling. In this study, we aimed to newly generate an anti–miR-21 oligonucleotide synthesized from serinol nucleic acid (anti–miR-21-SNA) to improve anti-microRNA activity and investigate its effects on cyst growth in vivo and in vitro. Methods: We evaluated the effectiveness of anti–miR-21 treatment using an serinol nucleic acid–based antisense oligonucleotide in a mouse model of cystic kidney disease and human ADPKD cells. Results: Our study revealed that anti–miR-21-SNA effectively prevented cyst growth in vivo and in vitro. In the mouse model of cystic kidney disease, we systemically administered anti–miR-21-SNA and observed its accumulation primarily in the kidneys, suggesting effective drug delivery. Anti–miR-21-SNA treatment reduced kidney size and blood urea nitrogen levels without inducing hepatotoxicity. Mechanistically, molecules related to mitochondrial metabolism, apoptosis, and fibrosis pathways were involved. In vitro, anti–miR-21-SNA treatment of primary cultured kidney cells from an ADPKD patient reduced cyst volume and intracellular cAMP content and increased Ca2+ concentration, supporting the efficacy of this treatment. Conclusions: Our results showed that anti–miR-21-SNA treatment represents a potential therapeutic strategy for cystic kidney disease.
- 3 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (6) , 900-913
Open AccessAmeliorative Effect of an Anti–MicroRNA-21 Oligonucleotide on Animal and Human Models of Cystic Kidney Disease
Key Points: Systemically administered anti–microRNA (miR)-21-serinol nucleic acid (SNA) accumulates in the kidneys and suppresses renal cyst growth. Anti–miR-21-SNA treatment alters mitochondrial metabolism, apoptotic signaling, and inhibits kidney tissue fibrosis. In human autosomal dominant polycystic kidney disease kidney cells, anti–miR-21-SNA treatment reduces cyst size and intracellular cAMP content and increases Ca2+ concentration. Background: Hereditary cystic kidney diseases are ciliopathies characterized by functional defects in the primary cilia of renal tubules. Abnormalities in the primary cilia enhance cell proliferation signals and cause cyst enlargement. The most common type is autosomal dominant polycystic kidney disease (ADPKD), but other diseases, such as nephronophthisis, have been discovered to be more common than previously considered. In ADPKD, several microRNAs are reportedly aberrantly expressed and involved in disease pathogenesis. Among these, we focused on microRNA (miR)-21, which is upregulated in response to cAMP signaling. In this study, we aimed to newly generate an anti–miR-21 oligonucleotide synthesized from serinol nucleic acid (anti–miR-21-SNA) to improve anti-microRNA activity and investigate its effects on cyst growth in vivo and in vitro. Methods: We evaluated the effectiveness of anti–miR-21 treatment using an serinol nucleic acid–based antisense oligonucleotide in a mouse model of cystic kidney disease and human ADPKD cells. Results: Our study revealed that anti–miR-21-SNA effectively prevented cyst growth in vivo and in vitro. In the mouse model of cystic kidney disease, we systemically administered anti–miR-21-SNA and observed its accumulation primarily in the kidneys, suggesting effective drug delivery. Anti–miR-21-SNA treatment reduced kidney size and blood urea nitrogen levels without inducing hepatotoxicity. Mechanistically, molecules related to mitochondrial metabolism, apoptosis, and fibrosis pathways were involved. In vitro, anti–miR-21-SNA treatment of primary cultured kidney cells from an ADPKD patient reduced cyst volume and intracellular cAMP content and increased Ca2+ concentration, supporting the efficacy of this treatment. Conclusions: Our results showed that anti–miR-21-SNA treatment represents a potential therapeutic strategy for cystic kidney disease.
- 10 August 2023
- Published by Wiley in Nephrology
- Vol. 28 (11) , 629-638
Basigin is released in extracellular vesicles derived from the renal tubular epithelium in response to albuminuria
Aim: Irrespective of the cause, albumin/proteinuria induces tubulointerstitial damage and accelerates the progression of kidney diseases. Our series of studies demonstrated that proteinuria, an independent prognostic factor for chronic kidney disease (CKD), is correlated with urinary basigin/CD147 (Bsg) levels. We examined the morphology and origin of Bsg in the tubular lumen through the effects of filtered glucose and protein solutes on the tubules. Methods: Diabetic kidney disease (DKD) patients (N = 50) were treated with spironolactone 25 mg for 4 weeks or by conservative treatment. The associations between urinary Bsg values and clinical indicators were examined. Primary-cultured proximal tubular epithelial cells (PTECs) from human adult kidneys were exposed to high glucose or bovine serum albumin (BSA). Results: In patients with early phase DKD, urinary Bsg levels were closely correlated with proteinuria but not HbA1c. Full-length Bsg on extracellular vesicles (EVs) was investigated primarily in urine collected from DKD patients. EVs obtained from the urine of DKD patients included Bsg and SGLT2 proteins. Notably, spironolactone treatment concomitantly suppressed the release of Bsg-bearing EVs in correlation with decreased albuminuria. Exposure of PTECs to BSA (but not high glucose) enhanced the storage of supernatant Bsg in EVs despite the absence of exposure-specific changes in Bsg transcription. Conclusion: Proteinuria induces the release of Bsg-bearing EVs derived from PTECs into the tubular lumen.
- 10 August 2023
- Published by Wiley in Nephrology
- Vol. 28 (11) , 629-638
Basigin is released in extracellular vesicles derived from the renal tubular epithelium in response to albuminuria
Aim: Irrespective of the cause, albumin/proteinuria induces tubulointerstitial damage and accelerates the progression of kidney diseases. Our series of studies demonstrated that proteinuria, an independent prognostic factor for chronic kidney disease (CKD), is correlated with urinary basigin/CD147 (Bsg) levels. We examined the morphology and origin of Bsg in the tubular lumen through the effects of filtered glucose and protein solutes on the tubules. Methods: Diabetic kidney disease (DKD) patients (N = 50) were treated with spironolactone 25 mg for 4 weeks or by conservative treatment. The associations between urinary Bsg values and clinical indicators were examined. Primary-cultured proximal tubular epithelial cells (PTECs) from human adult kidneys were exposed to high glucose or bovine serum albumin (BSA). Results: In patients with early phase DKD, urinary Bsg levels were closely correlated with proteinuria but not HbA1c. Full-length Bsg on extracellular vesicles (EVs) was investigated primarily in urine collected from DKD patients. EVs obtained from the urine of DKD patients included Bsg and SGLT2 proteins. Notably, spironolactone treatment concomitantly suppressed the release of Bsg-bearing EVs in correlation with decreased albuminuria. Exposure of PTECs to BSA (but not high glucose) enhanced the storage of supernatant Bsg in EVs despite the absence of exposure-specific changes in Bsg transcription. Conclusion: Proteinuria induces the release of Bsg-bearing EVs derived from PTECs into the tubular lumen.
- Open Access
- 11 November 2022
- Published by Springer Nature in BMC Biology
- Vol. 20 (1) , 1-23
Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis
Background: Combinatorial gene regulation by multiple microRNAs (miRNAs) is widespread and closely spaced target sites often act cooperatively to achieve stronger repression (“neighborhood” miRNA cotargeting). While miRNA cotarget sites are suggested to be more conserved and implicated in developmental control, the pathological significance of miRNA cotargeting remains elusive.Results: Here, we report the pathogenic impacts of combinatorial miRNA regulation on inflammation in systemic lupus erythematosus (SLE). In the SLE mouse model, we identified the downregulation of two miRNAs, miR-128 and miR-148a, by TLR7 stimulation in plasmacytoid dendritic cells. Functional analyses using human cell lines demonstrated that miR-128 and miR-148a additively target KLF4 via extensively overlapping target sites (“seed overlap” miRNA cotargeting) and suppress the inflammatory responses. At the transcriptome level, “seed overlap” miRNA cotargeting increases susceptibility to downregulation by two miRNAs, consistent with additive but not cooperative recruitment of two miRNAs. Systematic characterization further revealed that extensive “seed overlap” is a prevalent feature among broadly conserved miRNAs. Highly conserved target sites of broadly conserved miRNAs are largely divided into two classes—those conserved among eutherian mammals and from human toCoelacanth, and the latter, including KLF4-cotargeting sites, has a stronger association with both “seed overlap” and “neighborhood” miRNA cotargeting. Furthermore, a deeply conserved miRNA target class has a higher probability of haplo-insufficient genes.Conclusions: Our study collectively suggests the complexity of distinct modes of miRNA cotargeting and the importance of their perturbations in human diseases.
- 11 November 2022
- Published by Springer Nature in BMC Biology
- Vol. 20 (1) , 1-23
Open AccessSystematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis
Background: Combinatorial gene regulation by multiple microRNAs (miRNAs) is widespread and closely spaced target sites often act cooperatively to achieve stronger repression (“neighborhood” miRNA cotargeting). While miRNA cotarget sites are suggested to be more conserved and implicated in developmental control, the pathological significance of miRNA cotargeting remains elusive.Results: Here, we report the pathogenic impacts of combinatorial miRNA regulation on inflammation in systemic lupus erythematosus (SLE). In the SLE mouse model, we identified the downregulation of two miRNAs, miR-128 and miR-148a, by TLR7 stimulation in plasmacytoid dendritic cells. Functional analyses using human cell lines demonstrated that miR-128 and miR-148a additively target KLF4 via extensively overlapping target sites (“seed overlap” miRNA cotargeting) and suppress the inflammatory responses. At the transcriptome level, “seed overlap” miRNA cotargeting increases susceptibility to downregulation by two miRNAs, consistent with additive but not cooperative recruitment of two miRNAs. Systematic characterization further revealed that extensive “seed overlap” is a prevalent feature among broadly conserved miRNAs. Highly conserved target sites of broadly conserved miRNAs are largely divided into two classes—those conserved among eutherian mammals and from human toCoelacanth, and the latter, including KLF4-cotargeting sites, has a stronger association with both “seed overlap” and “neighborhood” miRNA cotargeting. Furthermore, a deeply conserved miRNA target class has a higher probability of haplo-insufficient genes.Conclusions: Our study collectively suggests the complexity of distinct modes of miRNA cotargeting and the importance of their perturbations in human diseases.
- Open Access
- 22 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (20)
Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis
Monocarboxylates, such as lactate and pyruvate, are precursors for biosynthetic pathways, including those for glucose, lipids, and amino acids via the tricarboxylic acid (TCA) cycle and adjacent metabolic networks. The transportation of monocarboxylates across the cellular membrane is performed primarily by monocarboxylate transporters (MCTs), the membrane localization and stabilization of which are facilitated by the transmembrane protein basigin (BSG). Here, we demonstrate that the MCT/BSG axis sits at a crucial intersection of cellular metabolism. Abolishment of MCT1 in the plasma membrane was achieved by Bsg depletion, which led to gluconeogenesis impairment via preventing the influx of lactate and pyruvate into the cell, consequently suppressing the TCA cycle. This net anaplerosis suppression was compensated in part by the increased utilization of glycogenic amino acids (e.g., alanine and glutamine) into the TCA cycle and by activated ketogenesis through fatty acid β-oxidation. Complementary to these observations, hyperglycemia and hepatic steatosis induced by a high-fat diet were ameliorated in Bsg -deficient mice. Furthermore, Bsg deficiency significantly improved insulin resistance induced by a high-fat diet. Taken together, the plasma membrane–selective modulation of lactate and pyruvate transport through BSG inhibition could potentiate metabolic flexibility to treat metabolic diseases.
- 22 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (20)
Open AccessBasigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis
Monocarboxylates, such as lactate and pyruvate, are precursors for biosynthetic pathways, including those for glucose, lipids, and amino acids via the tricarboxylic acid (TCA) cycle and adjacent metabolic networks. The transportation of monocarboxylates across the cellular membrane is performed primarily by monocarboxylate transporters (MCTs), the membrane localization and stabilization of which are facilitated by the transmembrane protein basigin (BSG). Here, we demonstrate that the MCT/BSG axis sits at a crucial intersection of cellular metabolism. Abolishment of MCT1 in the plasma membrane was achieved by Bsg depletion, which led to gluconeogenesis impairment via preventing the influx of lactate and pyruvate into the cell, consequently suppressing the TCA cycle. This net anaplerosis suppression was compensated in part by the increased utilization of glycogenic amino acids (e.g., alanine and glutamine) into the TCA cycle and by activated ketogenesis through fatty acid β-oxidation. Complementary to these observations, hyperglycemia and hepatic steatosis induced by a high-fat diet were ameliorated in Bsg -deficient mice. Furthermore, Bsg deficiency significantly improved insulin resistance induced by a high-fat diet. Taken together, the plasma membrane–selective modulation of lactate and pyruvate transport through BSG inhibition could potentiate metabolic flexibility to treat metabolic diseases.
- 1 July 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (7) , 1338-1350
CD147/Basigin Deficiency Prevents the Development of Podocyte Injury through FAK Signaling
- 1 July 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (7) , 1338-1350
CD147/Basigin Deficiency Prevents the Development of Podocyte Injury through FAK Signaling
- 12 December 2017
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 22 (4) , 815-824
The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases
- 12 December 2017
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 22 (4) , 815-824
The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases
- 1 May 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (suppl_3)
MO007INDUCTION OF IMMUNOSUPPRESSIVE MICRO-RNA IN SPLEEN ATTENUATES SEPSIS INDUCED ACUTE KIDNEY INJURY
- 1 May 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (suppl_3)
MO007INDUCTION OF IMMUNOSUPPRESSIVE MICRO-RNA IN SPLEEN ATTENUATES SEPSIS INDUCED ACUTE KIDNEY INJURY
- 1 April 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (4) , 740-751
Growth Factor Midkine Promotes T-Cell Activation through Nuclear Factor of Activated T Cells Signaling and Th1 Cell Differentiation in Lupus Nephritis
- 1 April 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (4) , 740-751
Growth Factor Midkine Promotes T-Cell Activation through Nuclear Factor of Activated T Cells Signaling and Th1 Cell Differentiation in Lupus Nephritis
- 16 August 2016
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 21 (4) , 597-607
Efficacy of urinary midkine as a biomarker in patients with acute kidney injury
Background The mortality and morbidity associated with acute kidney injury (AKI) remains high, despite advances in interventions. A multifunctional heparin-binding growth factor, midkine (MK), is involved in the pathogenesis of ischemic kidney injury. However, the clinical relevance of MK has not yet been elucidated. The present study investigated whether urinary MK can serve as a novel biomarker of AKI. Methods We initially compared the predictive value of MK with other urinary biomarkers, including N-acetyl-β-d-glucosaminidase (NAG), interleukin (IL)-18, and neutrophil gelatinase-associated lipocalin (NGAL), for the detection and differential diagnosis of established AKI (549 patients). Subsequently, the reliability of MK for the early detection of AKI was prospectively evaluated in 40 patients undergoing elective abdominal aortic aneurysm surgery. Urine samples were obtained at baseline, the period of aortic cross-clamping and declamping, the end of the surgery, and on post-operative day 1. Results The areas under the receiver operating characteristic curves for the diagnosis of AKI in various kidney diseases were 0.88, 0.70, 0.72, and 0.84 for MK, NAG, IL-18, and NGAL, respectively. When the optimal cutoff value of urinary MK was set at 11.5 pg/mL, the sensitivity and specificity were 0.87 and 0.85, respectively. In the second study, urinary MK peaked at the period of aortic declamping, about 1 h after cross-clamping in patients with AKI. Interestingly, the rise of MK in AKI patients was very precipitous compared with other biomarker candidates. Conclusion Urinary MK was prominent in its ability to detect AKI and may allow the start of preemptive medication.
- 16 August 2016
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 21 (4) , 597-607
Efficacy of urinary midkine as a biomarker in patients with acute kidney injury
Background The mortality and morbidity associated with acute kidney injury (AKI) remains high, despite advances in interventions. A multifunctional heparin-binding growth factor, midkine (MK), is involved in the pathogenesis of ischemic kidney injury. However, the clinical relevance of MK has not yet been elucidated. The present study investigated whether urinary MK can serve as a novel biomarker of AKI. Methods We initially compared the predictive value of MK with other urinary biomarkers, including N-acetyl-β-d-glucosaminidase (NAG), interleukin (IL)-18, and neutrophil gelatinase-associated lipocalin (NGAL), for the detection and differential diagnosis of established AKI (549 patients). Subsequently, the reliability of MK for the early detection of AKI was prospectively evaluated in 40 patients undergoing elective abdominal aortic aneurysm surgery. Urine samples were obtained at baseline, the period of aortic cross-clamping and declamping, the end of the surgery, and on post-operative day 1. Results The areas under the receiver operating characteristic curves for the diagnosis of AKI in various kidney diseases were 0.88, 0.70, 0.72, and 0.84 for MK, NAG, IL-18, and NGAL, respectively. When the optimal cutoff value of urinary MK was set at 11.5 pg/mL, the sensitivity and specificity were 0.87 and 0.85, respectively. In the second study, urinary MK peaked at the period of aortic declamping, about 1 h after cross-clamping in patients with AKI. Interestingly, the rise of MK in AKI patients was very precipitous compared with other biomarker candidates. Conclusion Urinary MK was prominent in its ability to detect AKI and may allow the start of preemptive medication.
- Open Access
- 23 September 2014
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (7) , 1097-1103
CD147 (EMMPRIN/Basigin) in kidney diseases: from an inflammation and immune system viewpoint
The glycosylated transmembrane protein CD147/basigin, also known as extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN), contributes to cell survival, migration and cancer invasion. In normal kidneys, high expression of CD147 is detected only in the basolateral side of tubular epithelial cells (TECs). The pathophysiological roles of CD147 in the kidneys are diverse, ranging from involvement in the occurrence of acute kidney injury (AKI) that is frequently accompanied by ischemia, inflammation and a loss of self-tolerance to the progression of chronic kidney disease (CKD) that is caused by an imbalance in extracellular matrix protein turnover. In AKI induced by ischemia, it is the CD147 on neutrophils, rather than that on TECs, that coordinately participates in massive neutrophil recruitment via acting as a physiological ligand for E-selectin, which is specifically enhanced in the endothelium upon inflammatory stimulation. In the CKD that follows AKI, a molecular circuit involving CD147, MMPs and transforming growth factor-β may be involved in the pathogenesis of progressive fibrosis through hyaluronan production and macrophage infiltration. Whereas CD147 thus plays deleterious roles in ischemic and fibrotic kidney injuries, CD147 expression on lymphocytes might decrease the disease activity of lupus nephritis (LN) by functioning as a potential negative regulator of the extraordinary proliferation of lymphocytes that occurs in this disease. In line with these basic studies, our clinical data indicate the potential of plasma CD147 to function as a critical biomarker for both ischemic AKI and LN. CD147 is also involved in crosstalk between the kidneys and distant organs, which may be mediated by chemotactic cytokines that are derived from circulating inflammatory cells and damaged organs. Disruption of such a vicious chain reaction involving CD147 would therefore be required in order to overcome kidney diseases. Multidisciplinary research regarding CD147 functions may open a new avenue for targeting therapeutics for kidney diseases.
- 23 September 2014
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (7) , 1097-1103
Open AccessCD147 (EMMPRIN/Basigin) in kidney diseases: from an inflammation and immune system viewpoint
The glycosylated transmembrane protein CD147/basigin, also known as extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN), contributes to cell survival, migration and cancer invasion. In normal kidneys, high expression of CD147 is detected only in the basolateral side of tubular epithelial cells (TECs). The pathophysiological roles of CD147 in the kidneys are diverse, ranging from involvement in the occurrence of acute kidney injury (AKI) that is frequently accompanied by ischemia, inflammation and a loss of self-tolerance to the progression of chronic kidney disease (CKD) that is caused by an imbalance in extracellular matrix protein turnover. In AKI induced by ischemia, it is the CD147 on neutrophils, rather than that on TECs, that coordinately participates in massive neutrophil recruitment via acting as a physiological ligand for E-selectin, which is specifically enhanced in the endothelium upon inflammatory stimulation. In the CKD that follows AKI, a molecular circuit involving CD147, MMPs and transforming growth factor-β may be involved in the pathogenesis of progressive fibrosis through hyaluronan production and macrophage infiltration. Whereas CD147 thus plays deleterious roles in ischemic and fibrotic kidney injuries, CD147 expression on lymphocytes might decrease the disease activity of lupus nephritis (LN) by functioning as a potential negative regulator of the extraordinary proliferation of lymphocytes that occurs in this disease. In line with these basic studies, our clinical data indicate the potential of plasma CD147 to function as a critical biomarker for both ischemic AKI and LN. CD147 is also involved in crosstalk between the kidneys and distant organs, which may be mediated by chemotactic cytokines that are derived from circulating inflammatory cells and damaged organs. Disruption of such a vicious chain reaction involving CD147 would therefore be required in order to overcome kidney diseases. Multidisciplinary research regarding CD147 functions may open a new avenue for targeting therapeutics for kidney diseases.